Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, K. B. Nolop, Wayne Spevak et al.|Nature|2010Cited by 1.8k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsFei Su, Jeffrey A. Sosman, Amaya Virós et al.|New England Journal of Medicine|2012Cited by 1k
Abl tyrosine kinases are required for infection by Shigella flexneriElizabeth A. Burton, Ann Marie Pendergast|The EMBO Journal|2003Cited by 125